Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.

British journal of clinical pharmacology - 1 Dec 2015

Monostory Katalin, Tóth Katalin, Kiss Ádám, Háfra Edit, Csikány Nóra, Paulik József, Sárváry Enikő, Kóbori László

Abstract excerpt

AIMS: Inter-individual variability in dose requirements of calcineurin inhibitors (CNI) has been linked to genetic polymorphisms of CYP3A enzymes. CYP3A5*3, CYP3A4*1B and CYP3A4*22 alleles of liver grafts may explain about one third of the inter-individual differences in pharmacokinetics of ciclosporin and tacrolimus in recipients. However, non-genetic factors, influencing CYP3A expression, can contribute to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Calcineurin Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Drug Monitoring

Share to Immunosuppressive Agents

Share to Liver Transplantation

Share to Tissue Donors

Source

Open in PubMed Open full text

Identifiers

PMID: 26271661
DOI: 10.1111/bcp.12747
PMCID: PMC4693492

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.PMID 26271661Read ↗

Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.Semantic proximity Read ↗

Pharmacogenetics of calcineurin inhibitors in renal transplantation.Semantic proximity Read ↗

Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients.Semantic proximity Read ↗

Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.Semantic proximity Read ↗

Explaining variability in ciclosporin exposure in adult kidney transplant recipients.Semantic proximity Read ↗

CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients.Semantic proximity Read ↗

CYP3A genotypes of donors but not those of the patients increase the risk of acute rejection in renal transplant recipients on calcineurin inhibitors: a pilot study.Semantic proximity Read ↗

Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.Semantic proximity Read ↗

Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.Semantic proximity Read ↗

Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.Semantic proximity Read ↗

Pharmacogenetic biomarkers: cytochrome P450 3A5.Semantic proximity Read ↗

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.